Radionetics Oncology
Yifeng Xiong, Ph.D. is the Sr. Director of Chemistry at Radionetics Oncology. Prior to this role, Yifeng held positions at Pipeline Therapeutics and Arena Pharmaceuticals, focusing on the development of small molecules for various neurological and psychiatric diseases. Yifeng has a Ph.D. in Organic Chemistry from the University of California Irvine.
Radionetics Oncology
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.